Vancomycin in the treatment of adult intra-abdominal infections: do we have strong evidences?

Song Liu
Meng Wang
Wenxian Guan
Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China

Abstract: The management of intra-abdominal infections (IAIs) primarily includes adequate antimicrobial therapy and appropriate source control. Vancomycin is a fundamental and most effective antimicrobial agent. The aim of this study is to search and evaluate the quality of clinical evidences regarding the exclusive use of vancomycin for the management of adult IAIs. For this purpose, we first summarized the recommendations on exclusive use of vancomycin in adult IAIs from six leading guidelines and excavated the relevant supporting references. We subsequently conducted a literature search to screen eligible clinical studies in this field for possible systematic review. Our investigation demonstrates that the exclusive use of vancomycin is recommended in restricted indications, that is, IAIs caused by Enterococcus spp. or methicillin-resistant Staphylococcus aureus. However, the supporting references in the guidelines are more subjective instead of objective, which mainly originate from experts’ personal experiences or from the therapeutic efficacy of vancomycin in other types of infections rather than in IAIs. Furthermore, our literature search fails to find high-level evidence. In conclusion, current low-level evidences are inadequate to elicit strong recommendations on the exclusive use of vancomycin in the treatment of adult IAIs. Our study would be helpful for the rational use of vancomycin and deceleration of the emerging vancomycin resistance rates.

Keywords: intra-abdominal infection, vancomycin, guideline, anti-infective agents

Background
Intra-abdominal infections (IAIs) represent a variety of conditions that involve pathologic inflammation of intra-abdominal organs or peritoneum. IAIs are mainly classified into two types: uncomplicated IAIs and complicated IAIs. Uncomplicated IAIs are defined as an infectious process only limited within single organ and does not involve peritoneum. In contrast, in complicated IAIs, the infection extends beyond the organ and causes either localized or diffuse peritonitis.

For both uncomplicated and complicated IAIs, antimicrobials and source control are two fundamental strategies. In recent years, the increasing disease burden and resistance rate of microorganisms are in parallel with the emergence of new antibiotics and new source control approaches. In response to the arising challenges, academic societies have released individual guidelines on the rational use of antibiotics in the management of IAIs.

Vancomycin is generally considered as the last resort of antibiotics for the treatment of Gram-positive bacteria in serious and life-threatening infections. Because of its high efficacy toward Gram-positive microorganisms, the total usage increased from small quantities to over 14,000 kg within two decades in Western countries.
Nevertheless, vancomycin is currently confronting major challenges, including vancomycin-resistant *Enterococci*,\(^7\) vancomycin-tolerant *Streptococcus pneumoniae*,\(^8\) and vancomycin-resistant *Staphylococcus aureus*.\(^9\)

To decelerate the emerging vancomycin resistance rate, current guidelines restrict the indications of vancomycin. In the current study, we first overviewed guideline recommendations on the exclusive use of vancomycin in the management of adult IAIs, with particular evaluation on the quality of supporting evidences. We subsequently performed a literature search to screen eligible studies in this field for possible systematic review.

**What do international guidelines say?**

We have reviewed the following six most recent guidelines or consensus released by a variety of geographically diversified professional societies in the management of IAIs: 1) Surgical Infection Society, version 2017 (SIS 2017),\(^10\) 2) World Society of Emergency Surgery, version 2017 (WSES 2017),\(^11\) 3) Global Alliance, version 2016 (AGORA 2016),\(^12\) 4) French National Guideline, version 2015 (France 2015),\(^13\) 5) Asian Perspective, version 2014 (Asia 2014),\(^14\) and 6) Infectious Diseases Society of America, version 2010 (IDSA 2010).\(^15\) (Table 1).

SIS 2017 is the fourth edition of IAIs management guideline following 1992, 2002, and 2010 versions released by the SIS.\(^10\) In this latest guideline, vancomycin is primarily suggested as an adjuvant drug in certain scenarios in the treatment of IAIs. For instance, “consider use of aztreonam plus metronidazole plus vancomycin for empiric therapy for higher-risk IAIs patients, especially for those with serious β-lactam allergies”, “consider use of added ampicillin or vancomycin for empiric anti-enterococcal treatment in higher-risk patients if they are not being treated with piperacillin–tazobactam or imipenem–cilastatin”. There are only two scenarios in which exclusive vancomycin is recommended, that is, consider use of vancomycin or teicoplanin for empiric therapy of hospital-acquired IAIs in patients at risk for infection from *Enterococcus spp.* or for empiric therapy of patients known to be colonized or at high risk for infection with methicillin-resistant *Staphylococcus aureus* (MRSA). Nevertheless, the panel has also explained in the text that the efficacy of vancomycin in the treatment of either *Enterococcus* or intra-abdominal MRSA infections has not been definitively evaluated. There is no available publication to provide objective clinical evidence. The above recommendations mainly rely on experts’ personal experience or data from vancomycin in treating other types of MRSA infections (eg, skin/skin structure infection and urinary tract infection).

WSES 2017 is an update of the WSES 2013 guideline for the management of IAIs.\(^11\) In this guideline, vancomycin is mentioned as an adjuvant antibiotic to ceftazidime/avibactam and metronidazole in critically ill patients with hospital-acquired IAIs. Vancomycin is also suggested in the management of *Enterococcus spp.* infection (especially ampicillin-resistant *Enterococcus*), but supporting evidences are not provided or discussed. We assume that the panel failed

<table>
<thead>
<tr>
<th>Guidelines</th>
<th>Recommendations</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIS 2017(^10)</td>
<td>Consider use of vancomycin for empiric therapy of hospital-acquired IAIs in patients at risk for infection from <em>Enterococcus spp.</em> or for empiric therapy of patients known to be colonized or at high risk for infection with MRSA.</td>
<td>The panel admits that there is no available publication to provide objective clinical evidence in terms of the efficacy of vancomycin in treating either enterococcal or intra-abdominal MRSA infections.</td>
</tr>
<tr>
<td>WSES 2017(^11)</td>
<td>Consider use of vancomycin for the treatment of <em>Enterococcus spp.</em> infection, especially ampicillin-resistant <em>Enterococcus</em> infection.</td>
<td>The panel does not provide or discuss supporting references for the use of vancomycin in <em>Enterococcus</em> infection.</td>
</tr>
<tr>
<td>AGORA 2016(^12)</td>
<td>Rational use of glycopeptides (including vancomycin) is not mentioned at all.</td>
<td>-</td>
</tr>
<tr>
<td>France 2015(^13)</td>
<td>Vancomycin is recommended as empiric therapy for ampicillin-resistant <em>Enterococcus spp.</em> in patients with nosocomial peritonitis presenting risk factors of IAIs. Vancomycin is only mentioned once where it is recommended as an adjuvant drug to carbapenems in the treatment of severe health care-associated complicated IAIs.</td>
<td>The two supporting references are in vitro <em>Enterococcus</em> susceptibility to vancomycin. There is still a lack of direct clinical evidences of vancomycin in the management of IAIs. Vancomycin is not mentioned as an exclusive antimicrobial in the management of IAIs.</td>
</tr>
<tr>
<td>Asia 2014(^14)</td>
<td>Vancomycin is recommended in initial empiric anti-enterococcal therapy and in suspected or proven IAIs due to MRSA.</td>
<td>The panel claims that the supporting evidences were in vitro susceptibility test of individual isolates and clinical experience. The panel admits that there is no direct clinical data regarding the efficacy of vancomycin in treating <em>Enterococcus spp.</em> or intra-abdominal MRSA infection.</td>
</tr>
<tr>
<td>IDSA 2010(^15)</td>
<td>Vancomycin is recommended for higher-risk IAIs patients, especially for those with serious β-lactam allergies.</td>
<td>-</td>
</tr>
</tbody>
</table>

**Abbreviation:** MRSA, methicillin-resistant *Staphylococcus aureus.*
to obtain published data in supporting the use of vancomycin in Enterococcus infection and referred parallel guidelines.

AGORA 2016 study is short for “a global alliance for optimizing antimicrobials rational use in IAI’s”, 12 This study is carried out by an international task force from 79 countries and has illustrated the global burden of antimicrobial resistance based on shared regional epidemiological data. This study has also provided suggestions about rational use of each type of antimicrobials for IAI’s patients. However, glycopeptides (including vancomycin and teicoplanin) are not mentioned at all in their statements.

France 2015 refers to the French National Guideline conducted jointly by the French Society of Anesthesia and Intensive Care Medicine, French Intensive Care Society, French Infectious Diseases Society, and French Society of Digestive Surgery. 13 Exclusive vancomycin is recommended as empiric therapy for ampicillin-resistant Enterococcus spp. in patients with nosocomial peritonitis presenting risk factors of IAI’s. However, after tracking the two supporting references in the text, 16,17 we conclude that this statement is based on in vitro data of anti-enterococcus activities of vancomycin, instead of clinical comparative cohort study. Therefore, there is still a lack of direct clinical evidences of vancomycin in the management of IAI’s.

Asia 2014 is an Asian perspective in antibiotic management of complicated IAI’s in adults. 14 Based on Asian epidemiological data and resistance profile, the taskforce develops recommendations for antibiotic management of complicated IAI’s in Asia. In this perspective, vancomycin is only mentioned once where it is recommended as an adjuvant drug to carbapenems in the treatment of severe healthcare-associated complicated IAI’s. Vancomycin is not mentioned as an exclusive antimicrobial in the management of IAI’s.

IDSA 2010 is a joint guideline for the diagnosis and management of complicated IAI’s by the SIS and the IDSA. 15 Similar to SIS 2017, WSES 2017, and France 2015, the IDSA 2010 recommends vancomycin in initial empiric anti-enterococcus therapy and in suspected or proven IAI’s due to MRSA. Nevertheless, the panel has discussed in the text that their recommendation regarding the use of vancomycin in Enterococcus spp. was based on in vitro susceptibility test of individual isolates, and their recommendation regarding the use of vancomycin in MRSA was due to “vancomycin has been generally used to treat MRSA infection”. They admit that there is no specific data regarding the efficacy of antibiotics in treating intra-abdominal MRSA infection.

**Literature search**

We conducted a computerized bibliographic search for all retrospective or prospective observational and/or experimental randomized studies as well as meta-analysis in the field of vancomycin and IAI’s (including both uncomplicated and complicated IAI’s). We included MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov databases up to May 2017 for the search of publications and ongoing trials with language restriction of English. The exclusion criteria were peritoneal dialysis study, animal study, epidemiology study, nonadult (pediatrics) study, nonoriginal publication (review, editorial), and informal publication (conference abstract). The following keywords and MeSH terms were used: “intra abdominal infection”, “intraabdominal infection”, and “vancomycin”. We conducted an additional manual retrieval of relevant original references from current guidelines.

Figure 1 demonstrates the flowchart of eligible studies. A total of 1,409 references were identified, of which 685 were subsequently screened after removal of duplicates. Afterward, irrelevant pharmacodynamics studies (n=208), animal studies (n=141), epidemiology studies (n=136), and pediatric studies (n=49) were excluded. Irrelevant dissertation (n=48), review/editorial (n=31), case report (n=26), and conference abstract (n=17) were excluded as well. The remaining 29 articles together with 25 additional articles by manual retrieval from current guidelines were assessed for eligibility. After thorough full-text evaluation, 19 combination therapy (nonexclusive vancomycin) studies, 11 non-IAI-specific (IAI data unavailable) studies, 10 descriptive single-arm (noncomparative) studies, 9 in vitro/ex vivo studies, and 5 pharmacokinetics and/or pharmacodynamics and/or side-effect studies were excluded. Eventually, no eligible study remained for systematic review (Figure 1).

**Perspectives**

To summarize, the above six guidelines consistently recommend the exclusive use of vancomycin in two indications: IAI’s caused by Enterococcus spp. or IAI’s related to MRSA, especially in patients with drug-resistant Enterococcus spp. and/or severe hospital-acquired IAI.

Experimental susceptibility tests demonstrated that Staphylococcus aureus isolated from pus of severe IAI’s patients was 100% susceptible to vancomycin, which however was moderately effective compared with daptomycin against Gram-positive bacterial isolates from Asia-Pacific region. 19 Another in vitro study confirmed that all strains of MRSA causing severe IAI’s and subsequent multiple organ failure were susceptible to vancomycin. 20 However, in vivo study failed to reproduce consistent results of in vitro settings and was unable to demonstrate synergism.
or antagonism effect between glycopeptides and other antibiotics.21

By excavating the supporting references in the guidelines, we notice that current recommendations are more subjective instead of objective, which mainly originate from experts’ personal experiences or from the therapeutic efficacy of vancomycin in other types of infections rather than in IAI. Furthermore, after conducting literature search for eligible clinical studies, we discover that high-level evidence regarding the exclusive therapy of vancomycin in the treatment of IAI is absent, and current low-level evidences are inadequate to elicit strong recommendations on the exclusive use of vancomycin in the treatment of IAI. Our study would be helpful for rational use of vancomycin and deceleration of the emerging vancomycin resistance rates.

Compared to monotherapy, inclusion of vancomycin as part of broad-spectrum coverage failed to result in better clinical cure or reduced mortality,22 but even longer length of stay in intensive care unit.23 This was consistent with another in vivo experiment that demonstrated that glycopeptides were unable to synergize with beta-lactam antibiotics against *Staphylococcus aureus*-associated IAI,21 although several single-arm studies suggested that high-dose vancomycin might help to improve the clinical efficacy against MRSA.24,25

Vancomycin was first isolated in 1953 and was approved for clinical use by Food and Drug Administration (FDA) in 1958. The patent expired in early 1980s. Since then, several generic versions from various manufacturers have been authorized by FDA for the sale of vancomycin. We assume that the lack of industry-driven clinical trials in recent 30 years contributes to the deficiency of clinical evidences in this area. We believe that future randomized clinical studies are necessary to verify current recommendations and develop new scenarios in which exclusive vancomycin is appropriate for the management of IAI.

**Acknowledgments**

The authors lament the decease of the dearest friend Dr. Shifu SHA, MD, PhD, (School of Medicine, Nanjing University) who has provided significant contribution to this scientific work. The authors thank Dr Daren Juan Hsuen Low (the Agency for Science, Technology and Research, Singapore) for his language polishing and critical review of this article. Source of funding was from the National Natural Science...
Discipline
The authors report no conflicts of interest in this work.

References